SCHEMBL4580705

SCHEMBL4580705

COc1cc(C#N)ccc1N1C(=O)C(CCO)=C2CCCCC21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.43
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
PARP1 P09874 2/20 0.38
TNK1 Q13470 2/20 0.38
TNK2 Q07912 1/20 0.38
OPRM1 P35372 3/20 0.37
OPRL1 P41146 3/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
MAPT P10636 2/20 0.35
TNF P01375 1/20 0.35
LITAF Q99732 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580923 0.85 KDM4E (0.38) CYP11B2KDM4EALDH1A1HPGDALOX12
SCHEMBL4581309 0.83 MAPK1 (0.39)
SCHEMBL4580904 0.80 CYP19A1 (0.36) CYP11B2
SCHEMBL4580485 0.76 AR (0.41) AR
SCHEMBL4579775 0.73 KDM4E (0.37) CYP11B2KDM4EALDH1A1HPGDALOX12
SCHEMBL4581078 0.71 AR (0.35) AR
SCHEMBL4578452 0.70 OPRM1 (0.36) OPRM1SMN1; SMN2CYP3A4CYP2C19
SCHEMBL4581959 0.70 ELANE (0.37) CYP11B2KDM4EALDH1A1HPGDALOX12
SCHEMBL4579414 0.69 PARP10 (0.38) PARP1SMN1; SMN2
SCHEMBL4579431 0.68 NR3C2 (0.36) PPARDPPARAGAAPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076813-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-03-27 US claimed
WO-2008024970-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO claimed
US-20080076813-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-03-27 US disclosed
US-20080076813-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-03-27 US disclosed
US-20080076813-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-03-27 US disclosed
WO-2008024970-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076813-A1 Benzene, Pyridine, and Pyridazine Derivatives MKI67, CCNB1, CCNB3 CYP11B2 710/4885PPARD 573/4885PPARA 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.